The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409 · cited 1×
“TMZ activity was evaluated using established response criteria that also consider patient neurological function and steroid dosage [19].”
MethodCairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Packer, R. J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H. S., Jakacki, R., Kurczynski, E., Needle, M., Finlay, J., et al. (1997) · Journal of Neurosurgery · doi:10.3171/jns.1997.86.5.0747 · Cited by 636
Karim, A. B. M. F., Afra, D., Cornu, P., Bleehan, N., Schraub, S., De Witte, O., Darcel, F., Stenning, S., Pierart, M., & Van Glabbeke, M. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02692-x · Cited by 389
How often are nonenhancing supratentorial gliomas malignant? A population study
Scott, J. N., Brasher, P. M. A., Sevick, R. J., Rewcastle, N. B., & Forsyth, P. A. (2002) · Neurology · doi:10.1212/wnl.59.6.947 · Cited by 366
Osoba, D., Aaronson, N. K., Muller, M., Sneeuw, K., Hsu, M. A., Yung, W. K. A., Brada, M., & Newlands, E. (1996) · Quality of Life Research · doi:10.1007/bf00435979 · Cited by 343
Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients
Surma-aho, O., Niemelä, M., Vilkki, J., Kouri, M., Brander, A., Salonen, O., Paetau, A., Kallio, M., Pyykkönen, L., & Jääskeläinen, J. (2001) · Neurology · doi:10.1212/wnl.56.10.1285 · Cited by 319
van den Bent, M. J., Taphoorn, M. J. B., Brandes, A. A., Menten, J., Stupp, R., Frenay, M., Chinot, O., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.015 · Cited by 297
Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients
Lunsford, L. D., & Kondziolka, D. (2001) · Neurology · doi:10.1212/wnl.57.11.2150-a · Cited by 292
Phase I trial of temozolomide using an extended continuous oral schedule.
Brock, C., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H. S., Colquhoun, I. R., Roddie, M., Glaser, M. G., Brampton, M., & Rustin, G. J. S. (1998) · PubMed · Cited by 284
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
Quinn, J. A., Reardon, D. A., Friedman, A. H., Rich, J. N., Sampson, J. H., Provenzale, J. M., McLendon, R. E., Gururangan, S., Bigner, D. D., Herndon, J. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.009 · Cited by 258
Suspected low‐grade glioma: Is deferring treatment safe?
Recht, L. D., Lew, R., & Smith, T. W. (1992) · Annals of Neurology · doi:10.1002/ana.410310413 · Cited by 250
Buckner, J. C., Gesme, D., O’Fallon, J. R., Hammack, J. E., Stafford, S., Brown, P. D., Hawkins, R., Scheithauer, B. W., Erickson, B. J., Levitt, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.023 · Cited by 249
Low-grade oligodendroglioma responds to chemotherapy
Mason, W. P., Krol, G. S., & DeAngelis, L. M. (1996) · Neurology · doi:10.1212/wnl.46.1.203 · Cited by 218
Bauman, G., Lote, K., Larson, D., Stalpers, L., Leighton, C., Fisher, B., Wara, W., Macdonald, D., Stitt, L., & Cairncross, J. G. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00284-9 · Cited by 193
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
Glass, J., Hochberg, F. H., Gruber, M. L., et al. (1992) · Journal of neurosurgery · doi:10.3171/jns.1992.76.5.0741 · Cited by 187
Chinot, O.-L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.-M., & Grisoli, F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2449 · Cited by 179
High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma
Massimino, M., Spreafico, F., Cefalo, G., Riccardi, R., Tesoro-Tess, J. D., Gandola, L., Riva, D., Ruggiero, A., Valentini, L., Mazza, E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.087 · Cited by 176
Bauman, G. S., Lote, K., Larson, D., Statpers, L., Leighton, C., Fisher, B., Wara, W., Macdonald, D., Stitt, L., & Cairncross, J. G. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)90145-1 · Cited by 176
van den Bent, M. J., Chinot, O., Boogerd, W., Bravo Marques, J., Taphoorn, M. J. B., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., De Beule, N., & Baron, B. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg157 · Cited by 165
PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas
Soffietti, R., Rudà, R., Bradac, G. B., & Schiffer, D. (1998) · Neurosurgery · doi:10.1097/00006123-199811000-00035 · Cited by 161
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B., Raizer, J. J., Malkin, M. G., Bazylewicz, K. A., & Abrey, L. E. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.1.39 · Cited by 107
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-1-39 · Cited by 85
Tada, K., Shiraishi, S., Kamiryo, T., Nakamura, H., Hirano, H., Kuratsu, J., Kochi, M., Saya, H., & Ushio, Y. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.4.0651 · Cited by 68
Neurocognitive sequelae of cancer treatment
Packer, R. J., & Mehta, M. P. (2002) · Neurology · doi:10.1212/wnl.59.1.8 · Cited by 31
Understanding low-grade glioma
Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.7.1402 · Cited by 25
Weighing the benefits and risks of radiation therapy for low-grade glioma
Peterson, K., & DeAngelis, L. M. (2001) · Neurology · doi:10.1212/wnl.56.10.1255 · Cited by 15
Cited by
Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management
van Breemen, M. S., Wilms, E. B., & Vecht, C. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70103-5 · Cited by 913
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaih, A., Laigle-Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 535
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505
Epileptic seizures in diffuse low-grade gliomas in adults
Pallud, J., Audureau, E., Blonski, M., Sanai, N., Bauchet, L., Fontaine, D., Mandonnet, E., Dezamis, E., Psimaras, D., Guyotat, J., et al. (2014) · Brain · doi:10.1093/brain/awt345 · Cited by 380
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., & on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 373
Metadata
- Authors
- Pace, A., Vidiri, A., Galiè, E., Carosi, M., Telera, S., Cianciulli, A. M., Canalini, P., Giannarelli, D., Jandolo, B., & Carapella, C. M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 14
- Issue
- 12
- Pages
- 1722-1726
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2104316756
- Cited by
- 263
- References
- 27
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.